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Background: Comparing international estimates of survival can be a useful way of highlighting differences in life expectancy between cystic
fibrosis (CF) populations. In this study, we compared survival in two CF populations.
Methods: The current lifetable method takes age-specific mortality rates observed in a given year and applies them to a hypothetical population
assuming those rates will remain the same in the future. This was used to compare median predicted survival in the United States (US) and the
Republic of Ireland (RoI) (1986–2008). Median age at death among decedents was also examined.
Results: In both countries, median age at death was lower than median predicted survival. Successive increases in annual median predicted
survival were not observed; rather an overall improvement was discerned over time. In the RoI, where absolute numbers of deaths were small,
year-on-year fluctuations in age-specific mortality rates resulted in wide-ranging annual median predicted survival estimates.
Conclusion: Median age at death is not a good measure of CF survival. Though median predicted survival improved in each country over the
study period, between-country comparison at a given time point may be misleading for rare disorders like CF. Longitudinal outcomes must be
examined.
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Comparing international estimates of survival can be a useful
way of highlighting differences in life expectancy between cystic
fibrosis (CF) populations [1]. Yet such an undertaking is not
straightforward; initial challenges include accessing data on age and⁎ Corresponding author. School of Public Health, Physiotherapy and
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doi:10.1016/j.jcf.2010.08.021vital status [2]. Two measures of survival are used in CF; median
age at death and median predicted survival. Although both are
interpreted as measures of survival, their meanings differ and this
often leads to confusion.Median age at death is based on decedents
in aCF population (mortality records are used in its calculation) and
the duration of life remaining in those still alive is not a
consideration. Median predicted survival estimation takes age-
specific mortality rates observed in a calendar year and estimates
life expectancy for a hypothetical population by assuming that
current mortality rates validly estimate future rates and remain
constant over the population's lifetime [3]. It has been used by the
US CF Registry to monitor temporal trends in median predicted
survival since 1986, as birth cohort follow-up has not yielded a
median survival value (N50% of the cohort are alive to date).d by Elsevier B.V. All rights reserved.
Fig. 1. Median age at death and current lifetable estimates of median predicted
survival (in years) for the Republic of Ireland (A) and United States (B), 1986–2008.
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survival have not yet been standardised; estimates are often
derived from different baselines (birth or one year of age) or
collapsed into arbitrary age classes and/or time periods when
populations are small [2,4–7]. The United Kingdom (UK) CF
Trust recently overcame this challenge by applying the United
States (US) CF Foundation (CFF) Patient Registry current
lifetable methodology, thus directly comparing UK survival
estimates with that of the US [8,9]. Median predicted survival
estimates of 38.8 and 37.4 years were reported by the UK and
US registries respectively for 2008 [10,11].
While large, long-established registries provide greater statisti-
cal power in survival analyses, national survival statistics are
required by all countries to inform local service provision. The aim
of this studywas to directly compareCF survival estimates between
the US and the Republic of Ireland (RoI) (1986–2008) using the
CFF Patient Registry current lifetable methodology. UK median
predicted survival estimateswere available for 2007 and 2008 only,
therefore our comparison focussed on the US and the RoI.
2. Methods
Annual median age at death and annual median predicted
survival (and 95% CIs) were derived from the CFF Patient
Registry, which in 2008 contained information on N25,000
patients attending CF care centres (representing 90% of all US
CF patients). All deaths and death dates are confirmed by direct
contact with the care centres.
By 2008, six years after initiation of the Cystic Fibrosis Registry
of Ireland (CFRI) and following a stringent validation process to
determine population ascertainment, 90% (n=1062) of the RoI CF
population had registered. Study patients were identified through
the CFRI or a listing of deaths compiled from three sources; records
of registered deaths with CF as the underlying cause 1986–2008
provided by the Central Statistics Office, CF centre attendee
deaths (2002–7), and CF patient association recorded deaths
(1986–2007). Subjects on the CFRI not reported as deceased by
31st December 2008 were therefore presumed to be alive.
The CFF Patient Registry current lifetable method [10] was
applied to the RoI data to calculate median predicted survival
estimates from 1986 to 2008. To avoid bias introduced by
assuming that all persons with CF (PWCF) were followed from
birth, the observation period started with the date of diagnosis
(a programme of newborn screening has not yet been introduced
in the RoI). Potential for bias resulting from deaths occuring
between diagnosis and CFRI enrolment was avoided by the
utilisation of registered death records. Annual populations were
defined from 1986 to 2008, each comprising PWCF diagnosed in
the year of observation or the years preceding it. For decedents
with a missing date of diagnosis we adopted an alternative entry
date. For those who died before their first birthday, a missing date
of diagnosis was taken to be the date of birth. Those dying after
their first birthday with a missing date of diagnosis were stratified
into two groupings; 1 to 24 years and≥25 years. A missing date
of diagnosis was set as the mean age at diagnosis of those patients
with valid data in that group. The cut point of 25 years was
necessitated by the age distribution of age at death in valid cases.Median predicted survival was estimated for a hypothetical
population of PWCF by applying the observed age-specific
rates in that year. Cumulative survival was calculated at each
age. Median predicted survival was derived as the age at which
cumulative survival dropped below the 50% level. Ninety-five
percent confidence intervals (CIs) were calculated as per the
CFF methodology [10]. Patients who underwent a solid-organ
transplantation are not excluded/censored [10]. Calculations
were performed on the RoI data using SPSS (version 15, SPSS
Inc.) and validated using the CFF's lifetable procedure
programme in SAS (version 8.2, SAS Institute). Time trends
in survival were examined using Pearson's correlation coeffi-
cient. Median predicted survival regression line slopes were
compared according to Zar's method [12] using GraphPad
Prism (version 5.03, GraphPad Software Inc.).3. Results
In the RoI and the US respectively, 421 (average 18.3, range
7–31) and 8849 (average 384.7, range 329–459) deaths occurred
between 1986 and 2008. In both countries median age at death
increased between 1986 and 2008, but did not exceed 24 years in
the RoI (26 in theUS).Median age at deathwas lower thanmedian
predicted survival at each annual time point (Fig. 1, Table 1).
Table 1
Number of deaths and median predicted survival for persons with cystic fibrosis (CF) in the Republic of Ireland and the United States.
Republic of Ireland United States
Year Number of CF deaths Median predicted survival (95% CI) Number of CF deaths Median predicted survival (95% CI)
1986 20 20.1 (13.0, 34.4) 339 26.7 (25.3, 28.3)
1990 14 26.1 (10.7, na) 343 28.5 (26.5, 31.0)
1994 18 27.0 (17.0, 30.5) 411 27.7 (26.3, 29.7)
1998 25 28.2 (20.0, 32.4) 388 31.7 (29.5, 33.7)
2002 18 34.5 (21.7, na) 426 31.3 (29.7, 33.1)
2003 16 35.2 (24.9, na) 370 32.4 (30.3, 35.1)
2004 19 29.2 (26.2, na) 369 35.1 (33.0, 38.1)
2005 17 39.5 (25.7, na) 357 36.5 (33.7, 40.0)
2006 13 38.6 (33.8, na) 370 36.2 (33.6, 40.6)
2007 31 26.2 (19.1, 31.4) 397 37.3 (35.6, 39.2)
2008 21 35.2 (24.5, na) 420 37.4 (35.0, 40.1)
Na: not available due to small numbers of deaths.
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1996 and 2001 in the RoI.
Median predicted survival estimates fluctuated from year-to-
year and fluctuations were more marked in the RoI (r2 =0.42)
than in the US (r2 =0.86). The highest US median predicted
survival (37.3 years) was recorded in 2007 following successive
increases since 2002. In the RoI, median predicted survival
estimates ranged from 26.2 to 39.5 years from 2000 onwards.
Median predicted survival regression lines showed that CF
survival improved overall during the study period. The rate of
improvement was similar in the US and the RoI as regression
slopes did not differ significantly; slope point estimates of 0.48
(95% CI: 0.39, 0.57) and 0.5 (95% CI: 0.23, 0.79) were observed
respectively.
4. Discussion
In this study, we identified an important limitation of
comparing survival estimates for CF, a rare disease with an
evolving decedent age profile when using a standardised current
lifetable method to directly compare the US and the RoI median
predicted survival estimates.
The first problem arising from using current lifetables to
derive an annual median predicted survival estimate is that
temporal fluctuations in annual age-specific mortality rates
cannot be taken into account. The current lifetable technique
takes age-specific mortality rates observed in a calendar year
and estimates life expectancy by assuming that current mortality
rates validly estimate future rates and remain constant over the
population's lifetime [3]. However, CF survival in the RoI is
improving overall, mirroring a pattern of increased life
expectancy in the US and elsewhere in recent decades [6].
Survival has improved particularly in childhood, in the
2–15 year old age group [13,14].
While age-specific mortality rates used to derive current
lifetable estimates of median predicted survival will vary from
year-to-year in CF registries of all size, variability may be
particularly marked in countries with small absolute numbers of
deaths. Consequently, comparisons of survival estimates with
international leaders at specific time points may be misleading.
While US and RoI annual median predicted that survival wasbroadly similar, there were exceptions for example; in 2007 the
US median predicted that survival estimate was 37.4 (95%
CI: 35.7, 39.2 years) compared with 26.2 years (95% CI: 19.1,
31.4) in the RoI. An unusually large number of deaths,
particularly in childhood, occurred in the RoI in that year
(n=31) and was more than twice the number reported in the
previous year (n=13). Yet, median predicted survival in the
subsequent year (2008)was similar (37.4 and 35.2 years in theUS
and RoI respectively).
Previous comparisons of CF survival estimates have utilised
national mortality statistics to calculate median age at death, in
order to make inferences about survival [2]. Median age at death
fluctuates with the age structure of the CF population, and will
increase as greater proportions of PWCF reach adulthood.
However, this statistic becomes less meaningful when the
observed population's mortality rate is low. This became
apparent when median age at death was shown to underestimate
CF survival derived using the current lifetable method.
Using linear regression to examine temporal patterns, we
found that median predicted survival improved at the same rate
in both countries, but was slightly higher in the US. Registry
selection bias is an important consideration for current lifetable
analysis [1,6,15] as omission of unrecognised deceased PWCF
can positively bias estimates, and may be one reason for the
observed difference. In the RoI dataset, registry data with a
high level of ascertainment was used together with registered
death information. Also, CF services in the RoI are available
free of charge, so the identification of the CF population may be
easier.
5. Conclusion
Median age at death may not be a useful measure of survival
as it provides a lower estimate than median predicted survival.
Calculating median predicted survival can be a useful way for
individual countries to monitor temporal trends in survival.
However, comparison of median predicted survival between
small and large CF registries at a given time point can be
misleading because of instability in annual age-specific
mortality rates. Analysis of longitudinal outcomes could
provide better insights into survival trends.
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